Robert Rosenson, MD
Professor of Medicine
Director of Lipoprotein Disorders and Clinical Atherosclerosis Research
Division of Cardiovascular Medicine
University of Michigan
Ann Arbor, MI
Ryan C. Neal, MD
Assistant Professor of Medicine
Baylor College of Medicine
Physicians: 2 hours
Nurse Practitioners: 2 contact hours (1.0 contact hour pharmacology)
Interactive Virtual Clinic
Cardiovascular disease remains a leading killer in the United States, and epidemiologic studies continue to show a direct relationship between hyperlipidemia and coronary heart disease (CHD). The risk for CHD rises with increasing cholesterol levels. The advent of effective pharmacologic agents has begun changing some of the major trends in cardiovascular events; however, various ethnic groups have different CHD risk factors, and individuals may respond differently to similar treatments. As cultural diversity expands in this country, providers must be educated on these differences. Moreover, clinicians must also be cognizant of patient comorbidities and other contributing factors that may affect treatment response.
As more patients receive treatment for dyslipidemia, continuing education on this topic is paramount, since risk assessment and treatment goals can vary depending on ethnic variations and comorbid conditions such as metabolic syndrome, diabetes, and other chronic conditions. Furthermore, clinicians need to be kept abreast of significant efficacy and safety issues to ensure that patients receive appropriate evidence-based therapy to reach their target lipid levels.
. Target Audience
Primary care physicians and nurse practitioners
Upon completion of this educational activity, the participant should be able to:
Identify CHD risk groups, including those with relevant CHD risk equivalents, based on ATP III and Update guidelines
Delineate the differences in CHD risk factors found among various ethnic groups
Select appropriate therapy for patients with metabolic syndrome, diabetes, and other comorbidities
Discuss the importance of patient adherence to treatment in reaching target lipid goals and reducing the risk of cardiovascular events
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Robert Rosenson, MD, discloses that he has been on the speakers bureau for Abbott Laboratories, AstraZeneca, and Sankyo Pharma, Inc. He has served on advisory committees for Abbott Laboratories, AstraZeneca, LipoScience, GlaxoSmithKline, Roche Pharmaceuticals, Takeda Pharmaceuticals North America, Inc., and Anthera Pharmaceuticals, Inc. Dr Rosenson is a shareholder and owns stock options for LipoScience.
Ryan C. Neal, MD, discloses that he has been on the speakers bureau for AstraZeneca, Merck and Co., Inc., Schering-Plough Corporation, Bristol-Myers Squibb, and Reliant Pharmaceuticals, LLC. He has provided product consultation for AstraZeneca.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. AKH Inc. designates this educational activity for 2.0 contact hours which includes 1.0 pharmacology contact hour.
Commercial Support Statements
Supported by an educational grant from AstraZeneca
None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., the American Academy of Physician Assistants, or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.